Fig. (3).

Treatment effects of continuous subcutaneous GLP1 infusion for 6 weeks in patients with T2DM. (A, B) Plasma glucose concentrations. GLP-1 significantly reduced fasting plasma glucose compared with saline or baseline. (C, D) Plasma C-peptide concentrations during a hyperglycemic clamp. The insert shows the first-phase secretory response (incremental 0-10 min) for patients receiving GLP-1. GLP-1 significantly stimulated the β-cell secretory response compared with saline or baseline. Mean±SEM. (Reprinted with permission from reference [35].)